TP53 and fibrosarcoma: In an effort to predict potential mechanisms of resistance that may arise during clinical treatment with SINE compounds, we have established SINE compound-resistant cells from the parental SINE compound-sensitive HT1080 fibrosarcoma (wt p53) cell line [52].